172 related articles for article (PubMed ID: 20117211)
1. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.
Colombo M; Corsi F; Foschi D; Mazzantini E; Mazzucchelli S; Morasso C; Occhipinti E; Polito L; Prosperi D; Ronchi S; Verderio P
Pharmacol Res; 2010 Aug; 62(2):150-65. PubMed ID: 20117211
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
3. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
4. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris SR; Carey LA
Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal antibodies and breast cancer. Current therapeutic progress].
Collignon J; Gennigens C; Rorive A; Coucke P; Lifrange E; Maweja S; Fillet G; Jerusalem G
Rev Med Liege; 2009; 64(5-6):279-83. PubMed ID: 19642459
[TBL] [Abstract][Full Text] [Related]
7. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
8. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
Brufsky A
Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
[TBL] [Abstract][Full Text] [Related]
11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
14. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
17. Improving the efficacy of trastuzumab in breast cancer.
Suzuki E; Toi M
Cancer Sci; 2007 Jun; 98(6):767-71. PubMed ID: 17428260
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
20. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
Campone M; Juin P; André F; Bachelot T
Crit Rev Oncol Hematol; 2011 Jun; 78(3):195-205. PubMed ID: 20684884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
